(Q44924110)

7 December 2017

title

Guidelines on the diagnosis and management of AL amyloidosis (English)

1 reference

7 December 2017

author name string

Guidelines Working Group of UK Myeloma Forum

series ordinal

1

1 reference

7 December 2017

British Commitee for Standards in Haematology, British Society for Haematology

series ordinal

2

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

British Journal of Haematology

7 December 2017

published in

1 reference

7 December 2017

volume

125

1 reference

7 December 2017

issue

6

1 reference

7 December 2017

page(s)

681-700

1 reference

Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Thalidomide in multiple myeloma: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Autologous stem cell transplantation for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Long term results of heart transplantation in patients with amyloid heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

21 January 2018

The systemic amyloidoses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Amyloidosis: a review of recent diagnostic and therapeutic developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.04970.X

10.1111/J.1365-2141.2004.04970.X

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference